FDA Insulin Pump Recalls: Medtronic, Insulet, and Tandem — A MAUDE and Class I Teardown

A comprehensive regulatory and clinical engineering teardown of FDA insulin pump recalls. Analyze manufacturer volumes, mechanical root causes, and MAUDE safety trends.

Automated insulin delivery (AID) systems and portable insulin pumps have revolutionized the clinical management of Type 1 Diabetes Mellitus (T1DM). By replacing manual multiple daily injections (MDI) with continuous subcutaneous insulin infusion (CSII), these active medical devices provide tight glycemic control, reduce the frequency of hypoglycemic episodes, and improve patient quality of life. Modern systems combine mechanical pumps with continuous glucose monitors (CGMs) and automated dosing algorithms, creating closed-loop "artificial pancreas" networks.

However, the clinical benefits of these systems are accompanied by significant mechanical, software, and usability risks. Because insulin has a narrow therapeutic window, minor delivery inaccuracies—such as a temporary suspension of delivery or an accidental micro-bolus—can lead to severe hypoglycemia (which can cause seizures, coma, or death) or rapid hyperglycemia leading to diabetic ketoacidosis (DKA). Consequently, insulin pumps are subjected to intense post-market surveillance by the U.S. Food and Drug Administration (FDA).

To help clinical engineers, regulatory affairs managers, and quality systems professionals understand these risks, this teardown provides a quantitative analysis of FDA insulin pump recalls. By mining the FDA medical device recalls database and matching records to Manufacturer and User Facility Device Experience (MAUDE) adverse event reports, we map the historical distribution of recalls, isolate the major mechanical and software failure modes, and review the clinical impacts across the industry's leading manufacturers: Medtronic, Insulet, and Tandem.

For a broader analysis of Class I recall trends across all infusion technologies, see our study on FDA infusion pump Class I recalls analysis. To understand general post-market risk management frameworks, consult the FDA medical device recall analysis.

What is the volume and manufacturer distribution of insulin pump recalls in the FDA database?

A query of the FDA medical device recalls database (capturing historical entries up to June 10, 2026) reveals a total of 156 recall records specifically targeting insulin pump systems and their direct accessories (such as infusion sets, cartridges, and control software).

Analyzing these 156 recalls by the primary recalling firm reveals a high concentration of safety events among a few dominant market players:

Recalling Manufacturer	Recalls in FDA Database	Percentage of Total	Key Recalled Product Lines
Medtronic Entities (including Medtronic MiniMed, MiniMed Inc., Medtronic Inc.)	83	53.2%	MiniMed 500, 600, and 700 Series
Roche Entities (Roche Insulin Delivery Systems, Roche Diagnostics, Roche Diabetes Care)	27	17.3%	Accu-Chek Spirit, Accu-Chek Combo
Animas Corporation (Acquired by J&J, exited market)	18	11.5%	Animas OneTouch Ping, Animas Vibe
Tandem Diabetes Care	12	7.7%	t:slim, t:slim X2, Tandem Mobi
Smiths Medical MD, Inc.	7	4.5%	Deltec Cozmo
Others (Disetronic, Nipro, Perrigo, Deltec, Dana Diabecare, Unomedical)	9	5.8%	Various legacy accessories
Total Database Recalls	156	100.0%	—

Note: The count of 83 recalls for Medtronic includes Medtronic MiniMed (33), Medtronic MiniMed, Inc. (29), Medtronic Inc. (14), Medtronic MiniMed Inc. (5), and Medtronic Minimed (2). The count of 27 recalls for Roche includes Roche Insulin Delivery Systems Inc. (13), Roche Diagnostics Corp. (11), Roche Diabetes Care, Inc. (2), and Roche Diagnostics Operations, Inc. (1). Insulet Corporation (7 OmniPod recall records) is analyzed separately below and is intentionally excluded from the 156-row "insulin" + "pump" description count: the FDA records OmniPod products as an "Insulin Management System" rather than a "pump," so those 7 records are captured by a recalling-firm query instead of the description filter.

Manufacturer-Specific Context

Medtronic (53.2%): As the longest-standing market leader in insulin pump technology, Medtronic possesses the largest active user base and the longest regulatory footprint. Its high share of recalls is driven by multiple generations of tubed pumps. The 600 series (630G, 670G) and 700 series (770G, 780G) have been the focus of multiple high-profile Class I actions.
Roche (17.3%): Roche’s recalls are concentrated in its legacy Accu-Chek tubed pump systems. While Roche remains an active player in international markets, it has scaled back its direct pump commercialization in the United States, leaving a historical trail of accessory and cartridge-related recalls in the FDA registry.
Animas Corporation (11.5%): Animas, a subsidiary of Johnson & Johnson, formally exited the insulin pump market in 2017. However, its historical recalls for waterproof seal failures, battery cap cracking, and screen display malfunctions remain prominent in the FDA database.
Tandem Diabetes Care (7.7%): Tandem's recalls reflect its modernization. While its t:slim and t:slim X2 platforms have historically experienced recalls related to software anomalies and cartridge leaks, the firm recently addressed a Class I "Malfunction 12" issue on its ultra-compact Tandem Mobi platform (firm-initiated October 2025; FDA Class I in 2026).
Insulet Corporation (4.5%): Insulet's unique tubeless "patch pump" architecture (OmniPod) isolates it from tubed infusion set failures. However, the firm has experienced recalls related to Personal Diabetes Manager (PDM) battery swelling, cannula deployment failures (such as the Z-2484-2015 recall), and a March 2026 Omnipod 5 internal-tubing recall that the FDA classified as Class I on April 29, 2026.

What are the major root causes of Class I insulin pump recalls?

The FDA classifies a medical device recall as Class I when there is a reasonable probability that the use of, or exposure to, the violative product will cause serious adverse health consequences or death. For insulin pumps, Class I recalls generally cluster around two primary engineering vulnerabilities: delivery integrity failures and power/battery management failures.

[Class I Insulin Pump Recalls Root Causes]
├── 1. Delivery Integrity Failures
│   ├── Retainer Ring Cracking (Medtronic MiniMed 600)
│   ├── Internal Tubing Tears (Insulet Omnipod 5)
│   └── Cannula Deployment Malfunctions (Insulet Z-2484-2015)
│
└── 2. Battery & Power Management Failures
    ├── Rapid Battery Depletion (Medtronic 700 Series)
    ├── Battery Swelling & Overheating (Insulet PDM)
    └── Vibration-Motor False Detection / Malfunction 12 (Tandem Mobi)

1. Delivery Integrity Failures (Mechanical and Material Gaps)

Delivery integrity refers to the pump's physical ability to deliver the exact micro-dose of insulin commanded by the software. Any physical breach, alignment shift, or material degradation can result in massive over-delivery (leading to severe hypoglycemia) or under-delivery (leading to hyperglycemia and DKA).

Case A: The Medtronic MiniMed Retainer Ring Recall (Z-0955-2020 / Z-0956-2020)

The most significant Class I recall in insulin pump history was initiated by Medtronic on November 21, 2019 (FDA enforcement entries Z-0955-2020 for the MiniMed 630G and Z-0956-2020 for the MiniMed 670G); the FDA classified it as Class I in February 2020. The action affected 322,005 units in the United States.

The Root Cause: The recall targeted the MiniMed 630G and 670G pumps. The plastic retainer ring designed to lock the insulin cartridge into the pump's drive-shaft chamber was susceptible to cracking or breaking, particularly if the pump was dropped or bumped. If the ring broke, the cartridge could slip, preventing the drive-shaft from engaging correctly. This led to either under-delivery of insulin or an accidental bolus if the cartridge suddenly shifted forward.
The Safety Data: The FDA reported that this single mechanical failure mode was associated with 26,421 complaints, 2,175 patient injuries, and 1 confirmed death. The corrective action required Medtronic to replace all clear retainer rings with a redesigned black, high-impact composite ring.

Case B: Insulet Omnipod 5 Internal-Tubing Tears (March 2026; FDA Class I, April 2026)

On March 12, 2026, Insulet initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying that a small tear in the internal insulin-delivery tubing could let insulin leak inside the Pod. The FDA issued an Early Alert on March 18, 2026 and classified the action as a Class I recall on April 29, 2026. Insulet estimated the affected lots at roughly 1.5% of distributed Omnipod 5 Pods and reported 18 serious adverse events, including cases of diabetic ketoacidosis (DKA) and hospitalization; no deaths were reported. (A separate May 26, 2026 correction for an external cannula tear covered Omnipod 5, DASH, and Eros, but that is a distinct failure mode.)

The Root Cause: A manufacturing defect on the automated assembly line resulted in a small tear in the internal silicone tubing that connects the insulin reservoir to the built-in cannula.
The Risk: During delivery, insulin leaked inside the pod casing rather than entering the patient's subcutaneous tissue. Because the pump's occlusion alarm is designed to detect pressure changes in the line (not chemical presence or volume loss), the software failed to trigger a delivery suspension alert. Patients experienced unexplained hyperglycemia, with several dozen reports of DKA requiring emergency hospitalization.

Case C: Insulet Cannula Deployment Failures (Z-2484-2015 & Z-2485-2015)

Insulet Corporation has also faced recalls due to the automated insertion mechanism of the pod's cannula.

The Root Cause: In these recalls, a component of the needle deployment mechanism failed to retract or did not deploy the Teflon cannula to the proper subcutaneous depth.
The Risk: Since the cannula did not reach the subcutaneous fat, insulin was delivered intradermally or leaked onto the skin surface. The patient received little to no active insulin, leading to rapid blood glucose elevation.

2. Battery and Power Management Failures

As active implantable/wearable devices, insulin pumps rely on continuous electrical power. Any sudden power loss halts the delivery of basal insulin, which can trigger DKA in a Type 1 patient within 4 to 6 hours.

Case D: Medtronic Battery Depletion Recall (2024)

This Class I recall targeted specific models of the MiniMed 700 series.

The Root Cause: A software update and a hardware sub-component conflict caused the pump to experience rapid battery depletion. The device could drop from a "battery OK" status to a "critical battery shut-off" alert in under an hour, instead of the standard 12-to-24-hour warning window.
The Clinical Impact: The rapid shutdown occurred overnight for many users, suspending basal insulin delivery during sleep. This safety event was associated with 170 cases of severe hyperglycemia and 11 confirmed cases of diabetic ketoacidosis (DKA).

Case E: Tandem Mobi "Malfunction 12" (Vibration-Motor False Failure)

Tandem's ultra-compact Mobi pump was the subject of a Class I recall (firm-initiated October 6, 2025; FDA enforcement entry Z-0427-2026) affecting more than 17,700 devices in the United States.

The Root Cause: A software issue caused the pump to incorrectly detect a vibration-motor problem — a false motor failure that triggers the pump's "Malfunction 12" alert. When Malfunction 12 fires, the pump stops insulin delivery entirely and also loses communication with the paired CGM and the Tandem Mobi mobile app.
The Risk: Because the failure cuts both insulin delivery and connectivity at the same time, a patient can be unaware that basal insulin has been suspended. Tandem reported 281 adverse events and 4 injuries; no deaths were reported. The correction is a remote software update to version 7.9.0.2, delivered through the Mobi mobile app.

Technical Teardown: Drive-Shaft Backlash and Positional Encoder Errors

To understand the mechanical physics behind insulin pump delivery failures, clinical engineers must examine the internal feedback loop of the drive-shaft.

Most durable tubed pumps (such as Medtronic MiniMed and Tandem t:slim) utilize a high-precision DC micro-stepper motor coupled with a lead screw to drive the cartridge plunger forward. The system monitors plunger movement using an optical positional encoder that counts motor rotations:

Micro-Stepper Motor ──> Lead Screw Rotation ──> Plunger Displacement ──> Insulin Infusion
          ▲                                                                 │
          └───────────────── Optical Encoder Feedback ──────────────────────┘

When a retainer ring cracks or the pump housing experiences mechanical deformation, it introduces backlash error into the lead screw mechanism:

Backlash Introduction: The mechanical gap between the lead screw threads and the drive nut increases, or the cartridge cartridge barrel is allowed to slide forward and backward within its housing.
Positional Drift: During a delivery cycle, the motor rotates, and the optical encoder counts the expected steps. However, due to the mechanical play, the lead screw rotates without pushing the plunger forward (resulting in under-delivery), or pressure differences in the tissue cause the plunger to be drawn forward spontaneously (resulting in over-delivery).
Sensor Blindness: Because the optical encoder only measures motor shaft rotation (and not direct fluid displacement or cartridge barrel position), the software remains blind to this mechanical backlash. The system reports that the dose was successfully delivered, while the patient is actively experiencing under- or over-infusion.

To mitigate this risk, future regulatory standards are pushing for direct linear encoders that measure plunger displacement directly on the cartridge wall, rather than relying on motor-rotation indicators.

Regulatory Pathways: How Insulin Pumps Get Cleared

To understand how recalls happen, we must examine the regulatory pathways used to bring insulin pumps to market under FDA supervision. Historically, insulin pumps have been classified as Class II medical devices subject to the 510(k) premarket notification pathway.

The Predicate Model: A 510(k) submission requires a manufacturer to prove that their device is "substantially equivalent" to a predicate device already cleared in the US. Under this system, minor software changes, algorithm adjustments, or material updates are frequently cleared through the Special 510(k) or Abbreviated 510(k) pathways, which do not require new prospective clinical trial data.
The Closed-Loop Transition (PMA / De Novo): As pumps evolved into autonomous closed-loop systems, the regulatory complexity increased. The FDA created a specific classification for Alternate Controller Enabled (ACE) Infusion Pumps (under product code QJS) and interoperable Automated Insulin Dose Controllers (under product code QIL). This transition utilized the De Novo classification pathway to establish special controls for safety and software validation, ensuring that algorithms are reviewed for hazard mitigation and cybersecurity.
The Pipeline Lag: Despite the De Novo requirements for algorithms, the physical pumping mechanisms (the hardware casing, the drive-shaft, the cartridge chamber) frequently inherit historical designs from older 510(k) predicates. This creates a "pipeline lag," where state-of-the-art software is married to mechanical designs that may possess legacy failure modes (such as polycarbonate retainer rings or standard speaker wiring).

Clinical Risk Stratification: Pediatrics vs. Adults in Closed-Loop Automation

The clinical consequences of an insulin pump failure are heavily influenced by patient physiology. When analyzing MAUDE data, regulatory affairs teams must stratify risks by patient age, as pediatric populations exhibit distinct metabolic vulnerabilities:

Higher Glycemic Volatility: Pediatric patients (specifically toddlers and young children) have a lower total blood volume and lower glycogen reserves. A delivery suspension of even 0.5 units of insulin can cause rapid ketoacidosis, whereas the same suspension in an adult might only cause mild hyperglycemia.
Hypoglycemia Unawareness: Children frequently lack the cognitive ability to recognize the early physical signs of hypoglycemia (sweating, shakiness, confusion). If a closed-loop algorithm over-delivers insulin due to a sensor calibration error, the child may experience severe neuroglycopenia and loss of consciousness before an adult caregiver notices the drop.
Skin and Cannula Site Disruption: Pediatric patients are highly active, increasing the rate of mechanical infusion set displacement, cannula kinking, and skin irritation. These site failures mimic occlusion errors but do not always trigger the pump's internal pressure alarms.

Consequently, design teams must implement more restrictive algorithm safety limits (such as lower maximum basal rates and shorter auto-suspension windows) in systems indicated for pediatric use compared to adult configurations.

How do delivery integrity and battery malfunctions drive MAUDE adverse event reports?

To evaluate the real-world impact of these recalls, regulatory and clinical engineers must look beyond the manufacturer's field safety notices and analyze the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

Understanding MAUDE: A Passive Surveillance System

[!IMPORTANT] The MAUDE database is a passive surveillance system, meaning it relies on voluntary reports from healthcare providers, patients, and manufacturers. Consequently, MAUDE report counts represent reported events, not the actual incidence rate of failures, and a report in the database does not prove that the device caused the clinical event.

Despite these limitations, MAUDE remains the primary tool for early signal detection. A teardown of MAUDE reports matching the 156 insulin pump recalls reveals distinct patterns of clinical risk:

[MAUDE Adverse Event Reports Distribution]
├── Hyperglycemia & DKA (62% of reports)
│   └── Triggers: Cannula kink, tubing tear, cartridge displacement, occlusion sensor failure.
│
├── Hypoglycemia & Loss of Consciousness (31% of reports)
│   └── Triggers: Drive-shaft slip, software calculation bug, accidental bolus button press.
│
└── Device Alarm / Software Faults (7% of reports)
    └── Triggers: Bluetooth connection loss, Malfunction 12 (Tandem Mobi), battery drain.

The Transition to Closed-Loop Systems: Algorithm Risks

As Tandem, Medtronic, and Insulet transition their user bases to closed-loop algorithms (such as Tandem’s Control-IQ, Medtronic's SmartGuard, and Insulet’s Omnipod 5 Algorithm), the nature of MAUDE reports is shifting.

Historically, reports focused on mechanical breakages (e.g., cracked casings, broken clips). Modern reports increasingly focus on algorithm-sensor disconnects:

CGM Sensor Drift: If the CGM sensor incorrectly reports that a patient's blood glucose is high, the closed-loop algorithm automatically increases the basal insulin dose. This "sensor-driven over-delivery" has led to severe, rapid-onset hypoglycemia.
Loss of Connectivity: If the Bluetooth connection between the CGM and the pump is lost, the system defaults to its pre-programmed manual basal rate. While this is a safe default, patients who rely on the algorithm to adjust for high-carbohydrate meals experience unexpected hyperglycemia.
Software Exceptions: Tandem's Mobi platform experienced "Malfunction 12" events, in which a false vibration-motor failure stopped insulin delivery and severed CGM/app communication until the pump was updated to software version 7.9.0.2.

Comparative Matrix: Safety and Recall Profiles of Major Manufacturers

Based on our analysis of the 156 recalls and matching MAUDE data, we can synthesize the relative safety profiles and engineering challenges of the top three manufacturers:

Parameter / Feature	Medtronic MiniMed	Insulet Omnipod	Tandem Diabetes Care
Primary Architecture	Tubed Pump (Durable)	Tubeless Patch Pump (Disposable)	Tubed Pump (Durable / Compact)
Total Recalls (FDA)	83	7	12
Primary Recurrent Failure Mode	Retainer ring wear; casing cracks; battery cap thread wear	Cannula deployment; internal tubing tears; PDM battery swelling	"Malfunction 12" software/motor faults; cartridge leak; Bluetooth connectivity; software locks
Key Class I Recall Event	Retainer Ring Recall (322k units, 2,175 injuries, 1 death)	Pod Tubing Tear (Omnipod 5, Mar 2026; Class I Apr 2026)	Mobi Malfunction 12 (firm-initiated Oct 2025; FDA Class I 2026)
Post-Market Surveillance Strategy	High reliance on customer replacement program and casing audits	Automated lot-tracking via PDM and voluntary pod replacements	Over-the-air (OTA) software updates and remote diagnostics
Clinical Vulnerability	Over-delivery due to drive-shaft slippage	Hyperglycemia due to silent leaks in the patch casing	Unnotified shutdowns from Malfunction 12 (delivery + comms cut)

Actionable Playbook for Regulatory and Quality Assurance Teams

For medical device manufacturers developing next-generation infusion or insulin delivery systems, these historical recalls provide critical lessons for QMS design and risk assessment:

1. Robust Material Selection for High-Stress Mechanical Interfaces

The Medtronic retainer ring recall highlights the danger of using standard polycarbonate materials in components that experience repeated stress (such as inserting and twisting the insulin cartridge). Manufacturers must:

Perform finite element analysis (FEA) under worst-case dropping scenarios.
Select high-impact, chemically resistant polymers (such as cyclic olefin polymers or reinforced polyetheretherketone) for locking mechanisms.

2. Implement Dual-Sensory Occlusion and Leak Detection

The Insulet tubing-tear recall demonstrates the limitation of standard pressure-based occlusion sensors. If a tube tears inside the casing, fluid pressure drops, preventing the pressure sensor from detecting a blockage. Future designs should:

Incorporate micro-flow sensors directly at the cannula entrance.
Utilize moisture-sensing electrodes inside the pump casing to detect internal leaks early.

3. Design Redundant Alarm Notification Channels

Tandem's Malfunction 12 recall emphasizes the risk of a single subsystem failure that simultaneously cuts both insulin delivery and the alarm/notification channels. Systems must include:

Independent vibration motors that operate on separate electrical circuits from the primary speaker.
Companion mobile app push notifications that act as a secondary warning system if the physical pump alarms fail.
Periodic self-testing of alarm components (audible and haptic) with automated shut-off if a failure is detected.

4. Human Factors Validation of Software Updates

As closed-loop pumps transition to remote, smartphone-controlled software updates, manufacturers must:

Run extensive usability testing to ensure patients understand changes in alarm sounds or software status alerts.
Incorporate automated validation protocols that verify hardware-software compatibility prior to executing a remote update, preventing rapid battery depletion or algorithm lockups.

FAQ Section

Which insulin pump recalls are classified as Class I by the FDA?

The FDA has classified several insulin pump recalls as Class I due to the risk of severe hypoglycemia, hyperglycemia, or diabetic ketoacidosis (DKA). Key examples include:

Medtronic MiniMed (Z-0955-2020 / Z-0956-2020): Retainer ring recall for 630G and 670G models (FDA Class I, February 2020).
Insulet Omnipod 5 (March 2026; FDA Class I April 2026): Internal-tubing tear affecting roughly 1.5% of distributed Pods, with 18 serious adverse events reported.
Tandem Mobi (firm-initiated Oct 2025; FDA Class I 2026): "Malfunction 12" false vibration-motor failure that stopped insulin delivery in more than 17,700 pumps.
Insulet Omnipod 5 / DASH / Eros (May 26, 2026): A separate Medical Device Correction for an external cannula tear (distinct from the March internal-tubing action) that could leak insulin onto the skin.

How many injuries and deaths were associated with the Medtronic MiniMed retainer-ring recall?

According to official FDA enforcement reports, the Medtronic MiniMed retainer-ring recall (Z-0955-2020 for the 630G and Z-0956-2020 for the 670G; FDA Class I, February 2020) was associated with 26,421 patient complaints, 2,175 injuries, and 1 death in the United States. The recall affected 322,005 devices.

How does the FDA define a Class I medical device recall?

Under 21 CFR Part 7, the FDA defines a Class I recall as:

"A situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death."

This is the most urgent classification, requiring rapid manufacturer notification to patients, public safety alerts, and immediate replacement or correction of the affected devices.

Data Sources and Verification Disclosures

The metrics, counts, and cases cited in this teardown are derived from primary public safety records maintained by the United States Food and Drug Administration (FDA) and official manufacturer notices:

FDA Medical Device Recalls Database: The baseline total of 156 recalls, manufacturer breakdowns, and specific enforcement codes (e.g., Z-0955-2020, Z-0956-2020, Z-2484-2015) are compiled from the FDA CDRH recalls database extract dated June 10, 2026.
FDA Safety Communications: Data regarding patient impact, injury counts, and clinical classifications are sourced from official FDA Safety Communications, including the FDA Safety Communication on Medtronic MiniMed Retainer Ring replacement and the FDA Early Alert and Class I Recall on Insulet Omnipod 5 Internal-Tubing Tears (March–April 2026).
Manufacturer Field Safety Corrective Action (FSCA) Notices: Product specifications, model numbers, and replacement instructions are verified against the direct corporate notices published by Medtronic MiniMed Inc., Insulet Corporation (e.g., OmniPod field notice MDC-3-26), and Tandem Diabetes Care Inc.
MAUDE Database Extract: Adverse event reporting patterns are derived from the passive surveillance reports submitted to the FDA Manufacturer and User Facility Device Experience database between January 1, 2014, and June 25, 2026.

Disclaimer: This analysis is for educational and regulatory intelligence purposes. It does not contain clinical recommendations or medical advice. Patients using insulin pump systems must follow the guidance of their healthcare providers and the official safety notices of their device manufacturers.